71233-25-5

Basic information

• Product Name: 3-Oxo-Piperidine-1,4-Dicarboxylic Acid 1-Tert-Butyl Ester 4-Ethyl Ester
• Synonyms: 3-Oxo-Piperidine-1,4-Dicarboxylic Acid 1-Tert-Butyl Ester 4-Ethyl Ester;Ethyl 1-N-Boc-3-oxopiperidine-4-carboxylate;3-Oxo-piperidine-1-carboxylic acid tert-butyl este;Ethyl N-Boc-3-Oxopiperidine-4-carboxylate;1-(tert-butoxycarbonyl)-4-ethyl-3-oxopiperidine-4-carboxylic acid;1-tert-Butyl 4-ethyl 3-oxopiperidine-1,4-dicarboxylate;1,4-Piperidinedicarboxylic acid, 3-oxo-, 1-(1,1-diMethylethyl) 4-ethyl ester;1-tert-butyl 4-ethyl 3-hydroxy-5,6-dihydropyridine-1,4(2H)-dicarboxylate
• CAS NO: 71233-25-5
• Molecular Formula: C₁₃H₂₁NO₅
• Molecular Weight: 271.31
• Mol File: 71233-25-5.mol

Chemical Properties

• Boiling Point: 364.6 °C at 760 mmHg
• Flash Point: 174.3 °C
• Appearance: /Liquid
• Density: 1.152 g/cm³
• Vapor Pressure: 1.66E-05mmHg at 25°C
• Refractive Index: 1.482
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 11.17±0.20(Predicted)
• CAS DataBase Reference: 3-Oxo-Piperidine-1,4-Dicarboxylic Acid 1-Tert-Butyl Ester 4-Ethyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Oxo-Piperidine-1,4-Dicarboxylic Acid 1-Tert-Butyl Ester 4-Ethyl Ester(71233-25-5)
• EPA Substance Registry System: 3-Oxo-Piperidine-1,4-Dicarboxylic Acid 1-Tert-Butyl Ester 4-Ethyl Ester(71233-25-5)

Safety Data

• Hazardous Substances Data: 71233-25-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Oxo-Piperidine-1,4-Dicarboxylic Acid 1-Tert-Butyl Ester 4-Ethyl Ester is used as a reactant in the synthesis of heteroaryl N-sulfonamides, which are known to exhibit cell-death properties. These heteroaryl N-sulfonamides have potential applications in the development of new drugs targeting various diseases, including cancer and other proliferative disorders.
Used in Agrochemical Industry:
3-Oxo-Piperidine-1,4-Dicarboxylic Acid 1-Tert-Butyl Ester 4-Ethyl Ester is also used as a building block in the synthesis of agrochemicals, such as herbicides, insecticides, and fungicides. Its unique structure allows for the development of novel compounds with improved efficacy, selectivity, and environmental compatibility, contributing to more sustainable agricultural practices.

InChI:InChI=1/C13H21NO5/c1-5-18-11(16)9-6-7-14(8-10(9)15)12(17)19-13(2,3)4/h9H,5-8H2,1-4H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 52763-21-0 ethyl 1-benzyl-3-oxopiperidine-4-carboxylate hydrochloride 
• 39514-19-7 ethyl 1-benzyl-3-oxo-4-piperidinecarboxylate 
• 70637-75-1 ethyl 3-oxopiperidine-4-carboxylate 

Downstream Products

• 300552-43-6 2-methyl-4-phenyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine 
• 1023299-85-5 3-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine 
• 370881-90-6 5-[(1S)-1-phenyl-ethylamino]-3,6-dihydro-2H-pyridine-1,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester 
• 1510829-06-7 (3R,3'R,4‘S)-1‘-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluoromethyl)phenyl)amino)-2-oxo-[1,3‘-bipiperidine]-4’-carboxamide 
• 1510829-06-7 (3S,3'R,4‘S)-1‘-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluoromethyl)phenyl)amino)-2-oxo-[1,3‘-bipiperidine]-4’-carboxamide 
• 1510829-06-7 (3S,3'S,4‘R)-1‘-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluoromethyl)phenyl)amino)-2-oxo-[1,3‘-bipiperidine]-4’-carboxamide 
• 1510829-06-7 (3R,3'S,4‘R)-1‘-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluoromethyl)phenyl)amino)-2-oxo-[1,3‘-bipiperidine]-4’-carboxamide 
• 1510829-06-7 trans-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluoromethyl)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide 

Relevant articles and documents

PYRIMIDINE-BASED BICYCLES AS ANTIVIRAL AGENTS FOR THE TREATMENT AND PREVENTION OF HIV INFECTION

This invention relates to pyrimidine derivatives, having HIV replication inhibiting. The present invention provides new pyrimidine compounds, designed for the treatment and prevention of HIV-mediated diseases. The invention further relates to pharmaceutical compositions and drugs contained in them. The invention also relates to the use of abovementioned compounds for the treatment and/or prevention of HIV in subjects with HIV-infection (human immunodeficiency virus) or having risk of getting HIV-infection.

Preparation method of tertiary butyl 7-hydroxyhexahydrofuro-[3,2-b] pyridine-4(2H)-carboxylic ester

The invention relates to a preparation method of (3aR, 7S, 7aR)-tertiary butyl 7-hydroxyhexahydrofuro-[3,2-b] pyridine-4(2H)-carboxylic ester, and mainly solves the technical problem of no method suitable for industrial synthesis currently. The preparatio

PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain pyrazolo[1,5-a]pyrimidine-5,7- diamine compounds (referred to herein as "PPDA compounds") that, inter alia, inhibit (e.g., selectively inhibit) CDK (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CDK; and to treat disorders including: disorders that are associated with CDK; disorders that result from an inappropriate activity of a cyclin-dependent kinase (CDK); disorders that are associated with CDK mutation; disorders that are associated with CDK overexpression; disorders that are associated with upstream pathway activation of CDK; disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections (including HIV); neurodegenerative disorders (including Alzheimer's disease and Parkinson's disease); ischaemia; renal diseases; and cardiovascular disorders (including atherosclerosis). Optionally, the treatment further comprises treatment (e.g., simultaneous or sequential treatment) with a further active agent which is, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.

The Role of the acidity of N-heteroaryl sulfonamides as inhibitors of Bcl-2 family protein-protein interactions

Overexpression of the antiapoptotic members of the Bcl-2 family of proteins is commonly associated with cancer cell survival and resistance to chemotherapeutics. Here, we describe the structure-based optimization of a series of N-heteroaryl sulfonamides t

PYRIMIDINYL TYROSINE KINASE INHIBITORS

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

SULFONAMIDES AS INHIBITORS OF BCL-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER

The present invention includes novel compound and methods of treating a disease or disorder by antagonizing Bcl-2 family proteins, particularly compounds of Formula (I) or pharmaceutically acceptable salt thereof, as well as methods of treating a disease,

FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS

Disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo [3.2.0]heptane compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS

Certain disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo [3.2.0]heptane are described, which are useful as orexin inhibitors. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF

The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment of RAGE-mediated diseases such as Alzheimer's Disease. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.

A novel asymmetric synthesis of cis-(3R,4R)-N-(tert -butoxycarbonyl)-4- methyl-3-(methylamino)piperidine

cis-(3R,4R)-N-(tert-Butoxycarbonyl)-4-methyl-3-(methylamino)piperidine, a key intermediate for the synthesis of CP-690550 (a potent protein kinase inhibitor), is prepared via an asymmetric approach starting from ethyl 1-benzyl-3-oxopiperidine-4-carboxylat